Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
American Society of Hematology (ASH)
The
American Society of Hematology
(
ASH
) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal
Blood
, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal,
Blood Advances
.
Genetic Testing for Hereditary Alpha-Tryptasemia in Patients Presenting with Mast-Cell Mediator Symptoms in the Absence of Symptoms of Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Hereditary alpha-tryptasemia may promote development of systemic mastocytosis. Screening for variations in copy number of the alpha tryptase gene may provide early evidence for diagnosis of mastocytosis.
Read More ›
Allogeneic Stem-Cell Transplantation for Patients with AML in Second Complete Remission Transplanted from Unrelated Donors with Post-Transplant Cyclophosphamide
ASH 2021 – AML
AML patients who underwent allogeneic stem-cell transplantation from unrelated donors while in their second complete remission with post-transplant cyclophosphamide had similar outcomes to those who underwent transplantation while in first complete remission.
Read More ›
Assessing the Potential Role of Anti-CD117 CAR T-Cells for Targeted Therapy in Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
CAR T-cell immunotherapy is highly efficient because of its ability to target specific tumor antigens. Preliminary evidence suggests that CAR T-cells directed against CD117, the KIT receptor, may emerge as a therapeutic option for advanced systemic mastocytosis.
Read More ›
Ivosidenib plus Azacitidine versus Placebo plus Azacitidine in Patients with Newly Diagnosed AML with an IDH1 Mutation
ASH 2021 – AML
The phase 3 AGILE study demonstrated that ivosidenib + azacitidine therapy provided significant survival benefit compared with placebo plus azacitidine in patients with newly diagnosed
IDH1
mutation–positive AML who were ineligible for intensive chemotherapy.
Read More ›
Whole Genome Sequencing Detects Chromosomal Aberrations Associated with Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Cytogenetic aberrations are rarely found by cytogenetics in systemic mastocytosis but are associated with advanced disease. Whole genome sequencing detects both chromosomal aberrations and non-
KIT
gene mutations and can be used as an alternative to cytogenetics for assessing disease risk.
Read More ›
Venetoclax plus FLAG-IDA Induction/Consolidation in Newly Diagnosed AML
ASH 2021 – AML
Addition of venetoclax to FLAG-IDA yielded high minimal residual disease–negative composite complete response rates in newly diagnosed patients with AML, accompanied by a favorable safety profile.
Read More ›
PATHFINDER Study Reveals Potential for Avapritinib to Modify Progression of Advanced Systemic Mastocytosis
ASH 2021 – Systemic Mastocytosis: Wrap-Up
Avapritinib was recently approved for treatment in advanced systemic mastocytosis after demonstrating in clinicals trials the ability to improve hematologic and bone marrow responses in patients.
Read More ›
The FLT3/SYK Inhibitor HM43239 Shows Activity in Patients with Relapsed or Refractory FLT3-Mutated and Wild-Type AML
ASH 2021 – AML
Results from an ongoing first-in-human phase 1/2 study indicated that the FLT3/SYK inhibitor HM43239 yielded a favorable safety profile and encouraging antileukemic activity in patients with relapsed/refractory AML regardless of
FLT3
mutation status.
Read More ›
Avapritinib Effectively Manages Advanced Systemic Mastocytosis in Patients with KIT D816V Mutations
ASH 2021 – Systemic Mastocytosis: Wrap-Up
KIT D816V mutations are highly associated with most cases of systemic mastocytosis. Avapritinib demonstrates efficacy in controlling disease progression in patients with
KIT D816V
mutations.
Read More ›
Hypomethylating Agent Therapy plus Venetoclax plus FLT3 Inhibitor Was Active in Older/Unfit Patients with FLT3-Mutated AML
ASH 2021 – AML
Findings from a retrospective analysis suggested that venetoclax plus hypomethylating agent plus an FLT3 inhibitor led to significant improvement in clinical outcomes, in older and unfit patients with
FLT3
-mutated AML.
Read More ›
Page 7 of 44
2
3
4
5
6
7
8
9
10
11
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us